

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/018295 A1

(43) International Publication Date
27 January 2022 (27.01.2022)

(51) International Patent Classification:

A61K 38/00 (2006.01) *C07K 16/24* (2006.01)
A61K 39/00 (2006.01) *A61K 38/17* (2006.01)
A61K 39/395 (2006.01) *C07K 14/47* (2006.01)
A61P 35/00 (2006.01) *C12N 5/10* (2006.01)
A61P 37/06 (2006.01) *C12N 15/09* (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2021/070765

(22) International Filing Date:

23 July 2021 (23.07.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

20187684.4 24 July 2020 (24.07.2020) EP

(71) Applicant: **AB2 BIO SA** [CH/CH]; EPFL Innovation Park,
Building B, 4th Floor, 1015 Lausanne (CH).

(72) Inventors: **SCHIFFRIN, Eduardo**; c/o AB2 Bio SA,
EPFL Innovation Park, Building B, 4th Floor, 1015 Lau-
sanne (CH). **SOLDAN, Michael**; c/o AB2 Bio SA, EPFL
Innovation Park, Building B, 4th Floor, 1015 Lausanne
(CH).

(74) Agent: **VOSSIUS & PARTNER PATENTANWÄLTE
RECHTSANWÄLTE MBB**; Siebertstraße 3, 81675 Mu-
nich (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: AVOIDING OR MINIMIZING SIDE-EFFECTS RELATED TO CAR-T-CELL THERAPY

(57) Abstract: The present invention provides compounds and compositions for use in the treatment of cancer as part of a Chimeric Antigen Receptor T-cell (CAR-T) therapy. In particular, the present invention discloses IL-18 binding molecules such as, for example, the IL-18 binding protein (IL-18BP) for use in Chimeric Antigen Receptor T-cell (CAR-T) therapy as a modulator to avoid or minimize side effects.

WO 2022/018295 A1